Purity Is Not Proof: The Three Tests Every Peptide Therapy Must Pass

A peptide is simply a chain of amino acids.

It can be an established medicine.

It can be a promising experimental drug.

It can be a cosmetic ingredient.

It can also be an unidentified powder sold in a vial marked “research use only.”

The chemistry may place these products in the same broad family. Their manufacturing standards, clinical evidence and risk profiles can be worlds apart.

That is why every peptide therapy must pass three separate tests:

1. Is the product genuine and properly manufactured?
2. Does the molecule produce meaningful benefits in humans?
3. Is it appropriate for this patient, purpose and dose?

“

Passing one test does not mean a product passes the others.

The first question is not whether the peptide works.

It is whether the product contains what the label says it contains.

A laboratory report showing “99% purity” can sound conclusive. But purity is only one part of product quality.

For an injectable peptide, meaningful quality control may need to address:

• molecular identity
• concentration and dose accuracy
• related impurities
• degradation products
• residual manufacturing chemicals
• peptide aggregation
• bacterial endotoxins
• microbial contamination
• stability
• sterility

This distinction matters because peptides can degrade through heat, time, light, handling, formulation and changes in pH. A product may have been correctly manufactured and still arrive compromised after poor storage or transportation.

FDA reviewers raised several of these concerns while examining compounded MOTS-c products, including limited information about certificates of analysis, impurities, aggregates, formulation and potential immunogenicity. [1]

“Third-party tested” is therefore not a complete answer.

Ask:

• Who performed the testing?
• Was the laboratory independent and appropriately accredited?
• Was every batch tested, or only a sample selected by the seller?
• Did the laboratory test identity, concentration and sterility—or only report a purity percentage?
• Can the customer match the report to the batch number printed on the vial?

Without those details, testing language can function more as marketing than verification.

Manufacturing quality is essential.

But even a perfectly manufactured vial proves only that the intended substance is present.

It does not prove that the substance produces the claimed result.

This is where many peptide claims move too quickly.

A biological mechanism becomes a benefit.

A cell experiment becomes a therapy.

A mouse study becomes a human protocol.

A change in a biomarker becomes evidence of longer life.

“

Biological plausibility is the beginning of drug development, not the end.

Semaglutide and tirzepatide

Semaglutide and tirzepatide sit toward the established end of the peptide spectrum.

They have FDA-approved products with defined indications, prescribing information, dosing instructions, contraindications and known adverse effects. [2][3]

That does not mean they are suitable for every person.

It means clinicians can evaluate them using a substantial body of human evidence.

They are not credible merely because they are peptides.

They are credible because specific products have passed controlled trials, manufacturing review and regulatory evaluation for specific uses.

Retatrutide

Retatrutide shows why the distinction between promising and proven matters.

It is designed to activate GLP-1, GIP and glucagon receptors in a single molecule. Lilly has reported positive results from multiple Phase 3 trials and plans to seek regulatory approval. [4]

The compound may become an important medicine.

That does not make a gray-market vial labeled “retatrutide” equivalent to the product studied in Lilly’s trials.

The name on the vial does not establish its identity, formulation, stability, dose or clinical equivalence.

MOTS-c and SS-31

MOTS-c and SS-31 are commonly grouped together under the phrase “mitochondrial peptides.”

That description can make them sound interchangeable. They are not.

MOTS-c is an experimental mitochondrial-derived peptide being studied in relation to metabolism, cellular stress and exercise biology. Interest in its mechanism is legitimate, but human evidence for administering synthetic MOTS-c as a general longevity or metabolic treatment remains limited.

Its review for possible pharmacy compounding is also not an FDA approval or a conclusion that it improves energy, insulin sensitivity or lifespan. [1]

SS-31, also known as elamipretide, has moved further through conventional drug development. The FDA granted accelerated approval to Forzinity (elamipretide) for improving muscle strength in patients with Barth syndrome who meet specified criteria. [5]

That is an important medical achievement.

It is not evidence that SS-31 has been proven to improve energy, athletic performance or aging in otherwise healthy adults.

“

Evidence for one narrowly defined disease should not be stretched into proof of universal mitochondrial optimization.

GHK-Cu

GHK-Cu is widely discussed in relation to collagen, wound repair, skin quality and hair growth.

It has plausible biological activity and a history of cosmetic and laboratory research. But the evidence depends heavily on the formulation and route of administration.

Topical GHK-Cu, a cosmetic formulation and an injectable product are not equivalent interventions.

They can produce different levels of absorption, tissue exposure and systemic risk.

A 2025 review noted that GHK-Cu is fairly hydrophilic and has limited permeation through the lipophilic stratum corneum, while also describing gaps in research on proposed delivery systems. [6]

Evidence that GHK-Cu affects cells or experimental models is scientifically interesting.

It does not automatically validate systemic injections for whole-body regeneration, hair restoration or biological age reversal.

Semax and Selank

Semax and Selank are usually marketed as cognitive or neuropsychiatric peptides.

Semax is associated with claims involving attention, memory, neuroprotection and recovery. Selank is associated with anxiety reduction, mood and mental clarity.

Both have appeared in scientific literature, but much of the evidence is regional, preclinical, mechanistic or based on relatively small studies.

FDA’s 2026 Semax review discusses substantial animal and preclinical literature, including rat models and cultured rat cells, rather than a large modern clinical evidence base for the broad wellness claims often made online. [7]

That does not mean the compounds are inactive.

It means claims such as “improves cognition” or “reduces anxiety” can be broader and more certain than the available evidence justifies.

Semax was also reviewed in July 2026 as a possible substance for pharmacy compounding. A compounding review considers whether pharmacies may use a bulk substance under a particular regulatory framework. It is not equivalent to approving the peptide for cognition, stroke recovery, depression or attention disorders. [7]

Epitalon and Pinealon

Epitalon and Pinealon occupy the longevity end of peptide marketing.

Claims commonly involve telomeres, sleep, gene expression, cognition, endocrine function and lifespan.

The difficulty is that longevity claims require exceptionally strong evidence.

A peptide may affect telomerase in a laboratory model without extending healthy human life.

It may change a biomarker without reducing cancer, cardiovascular disease, dementia or mortality.

It may improve a short-term measurement without producing any meaningful long-term benefit.

Research involving short peptide bioregulators may justify further study. It does not yet establish that modern Epitalon or Pinealon protocols slow human aging.

Epitalon’s consideration within the 2026 FDA compounding process should be understood as regulatory evaluation, not FDA approval and not proof of lifespan extension. [8]

Thymosin alpha-1

Thymosin alpha-1 has a longer clinical history than many peptides marketed through wellness clinics.

It has been studied for immune modulation, infections and serious illness. But “supports the immune system” is not a sufficiently precise clinical claim.

The immune system is not a volume control that should always be turned upward.

A large multicentre, double-blind, placebo-controlled Phase 3 trial involving 1,106 adults with sepsis found no clear evidence that thymosin alpha-1 reduced 28-day all-cause mortality. [9]

That result does not prove the molecule has no clinical applications.

It demonstrates why a plausible immune mechanism cannot substitute for a meaningful patient outcome.

Even a genuine and clinically effective drug can be the wrong treatment.

The final test is not about the molecule alone.

It is about the person receiving it.

Before treatment, ask:

• What condition is being treated?
• What result is expected?
• Is that result measurable?
• What evidence supports this exact use?
• What medications and medical conditions could change the risk?
• What monitoring is required?
• How long should treatment continue?
• What would cause it to be stopped?
• What established alternatives are available?

These questions are clearer for approved medicines because their studied doses, indications, contraindications and adverse effects are formally documented.

For experimental peptides, uncertainty accumulates.

The effective dose may be unknown.

Long-term safety may be unknown.

Interactions may be unknown.

The appropriate monitoring strategy may be unknown.

The expected benefit may be based largely on a mechanism, animal study or personal testimonial.

Medical supervision can reduce some of these risks.

It cannot create evidence that does not exist.

A prescription does not automatically convert an experimental intervention into an established therapy.

Rather than placing every peptide in one category, it is more useful to organize them according to the evidence supporting a specific use.

Established peptide medicines

Semaglutide and tirzepatide have approved products, substantial clinical programs and defined medical indications. [2][3]

Late-stage or indication-specific therapies

Retatrutide has encouraging Phase 3 results but remains investigational. [4]

SS-31 has an approved, disease-specific use as elamipretide. That approval should not be generalized to wellness or longevity protocols. [5]

Biologically plausible compounds with incomplete validation

GHK-Cu, MOTS-c, Semax, Selank and thymosin alpha-1 have varying levels of mechanistic, laboratory and human evidence.

None can be accurately summarized with a universal promise such as “better skin,” “more energy,” “better cognition” or “stronger immunity.”

Longevity hypotheses

Epitalon and Pinealon may deserve further investigation.

Claims that they extend lifespan or reverse human aging remain far ahead of the available evidence.

These categories are not permanent.

Some experimental peptides will fail.

Some may prove useful for narrow indications.

Some may eventually become important medicines.

That uncertainty is not a flaw in science.

It is how drug development works.

The peptide market is professionalizing.

That could make products safer and reduce reliance on anonymous research-chemical vendors.

But professional branding should be accompanied by professional standards.

A credible peptide provider should disclose:

• the regulatory status of the compound
• whether the proposed use is approved or experimental
• the level of human evidence
• the manufacturing source
• batch-specific quality testing
• sterility and endotoxin testing for injectables
• known risks and major unknowns
• the prescribing rationale
• the monitoring plan
• the process for reporting adverse events

The consent process should make one distinction especially clear:

Peptides may become one of the defining therapeutic platforms of modern medicine.

Semaglutide and tirzepatide have already demonstrated what is possible when peptide biology is combined with molecular engineering, controlled manufacturing, large clinical trials and regulatory scrutiny. [2][3]

Retatrutide may advance metabolic treatment further. [4]

Mitochondrial peptides, neuropeptides, copper-binding peptides, peptide bioregulators and immune-modulating peptides may eventually produce other valuable therapies.

But excitement should raise the evidentiary standard, not lower it.

The useful question is not:

“Do peptides work?”

The category is too broad for that question to mean anything.

The useful questions are:

1. Is this exact product what it claims to be?
2. Does this exact molecule improve meaningful outcomes in humans?
3. Is it appropriate for this exact patient, purpose and dose?

Until then, purity is valuable.

Medical oversight is valuable.

Safer access may be valuable.

But none of them - alone or together - are proof.